ARDELYX, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
ARDELYX, INC. (ARDX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $3.38 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- ARDELYX, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2026-03-31 was $4.27, a 255.83% increase year-over-year.
- ARDELYX, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2025-03-31 was $1.20, a 61.41% decline year-over-year.
- ARDELYX, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2024-03-31 was $3.11, a 88.48% increase year-over-year.
- ARDELYX, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2023-03-31 was $1.65.
- ARDELYX, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $2.20, a 1.79% decline from fiscal 2024.
- ARDELYX, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $2.24, a 39.13% increase from fiscal 2023.
- ARDELYX, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $1.61, a 62.63% increase from fiscal 2022.
- ARDELYX, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $0.99, a 49.49% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.38 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $4.27 10-Q · filed 2026-04-30 | |||
| 2025-12-31 | $2.20 10-K · filed 2026-02-19 | |||
| 2025-09-30 | $2.17 10-Q · filed 2025-10-30 | |||
| 2025-06-30 | $1.86 10-Q · filed 2025-08-04 | |||
| 2025-03-31 | $1.20 10-Q · filed 2025-05-01 | |||
| 2024-12-31 | $2.24 10-K · filed 2025-02-20 | |||
| 2024-09-30 | $2.38 10-Q · filed 2024-10-31 | |||
| 2024-06-30 | $2.42 10-Q · filed 2024-08-01 | |||
| 2024-03-31 | $3.11 10-Q · filed 2024-05-02 | |||
| 2023-12-31 | $1.61 10-K · filed 2024-02-22 | |||
| 2023-09-30 | $1.96 10-Q · filed 2023-10-31 | |||
| 2023-06-30 | $2.12 10-Q · filed 2023-08-02 | |||
| 2023-03-31 | $1.65 10-Q · filed 2023-05-03 | |||
| 2022-12-31 | $0.99 10-K · filed 2023-03-02 | |||
| 2022-09-30 | $0.00 10-Q · filed 2022-11-03 | |||
| 2022-06-30 | $0.00 10-Q · filed 2022-08-04 | |||
| 2022-03-31 | $0.00 10-Q · filed 2022-05-05 | |||
| 2021-12-31 | $1.96 10-K · filed 2022-02-28 | |||
| 2021-09-30 | $1.96 10-Q · filed 2021-11-12 | |||
| 2021-06-30 | $2.75 10-Q · filed 2021-08-13 | |||
| 2020-12-31 | $2.29 10-K · filed 2021-03-08 | |||
| 2019-12-31 | $2.59 10-K · filed 2020-03-06 | |||
| 2017-12-31 | $1.70 10-K · filed 2019-03-06 | |||
| 2016-12-31 | $2.19 10-K · filed 2019-03-06 | |||
| 2015-12-31 | $1.42 10-K · filed 2018-03-14 | |||
| 2014-12-31 | $0.71 10-K · filed 2017-02-17 | |||
| 2014-09-30 | $0.61 10-Q · filed 2014-11-07 | |||
| 2014-06-30 | $0.60 10-Q · filed 2014-08-08 | |||
| 2013-12-31 | $0.56 10-K · filed 2016-03-04 | |||
| 2012-12-31 | $0.52 10-K · filed 2015-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |